UNSPSC 51422119: Meprednisone disodium phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H27O8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W80C977F6O, chemically known as pregna-1,4-diene-3,11,20-trione, 17-hydroxy-16-methyl-21-(phosphonooxy)-, disodium salt, (16.beta.)-, but more generally known as meprednisone disodium phosphate, which bears US NIH Compound Identifier 31051.

European Medicines Agency schedules meprednisone disodium phosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08756MIG. Most nations, for tariff purposes, schedule meprednisone disodium phosphate under HS 29372900. SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@H]3C(=O)C[C@@]2([C@]1(C(=O)COP(=O)([O-])[O-])O)C)C.[NA+].[NA+].

UNSPSC 51422119 Meprednisone disodium phosphate is a Commodity code that carries a significant mismatch between its nominal pharmaceutical scope and recent state and local solicitation activity. The code has posted no recent opportunities for the corticosteroid pharmaceutical itself; instead, the two most recent opportunities tagged to this code involve naloxone procurement and direct-to-manufacturer prescription program strategy, neither of which aligns with meprednisone disodium phosphate supply. State and local buyers using this code appear to be treating it as a catchall for pharmaceutical and pharmacy-related procurements rather than a narrowly defined drug product, signaling either misclassification by issuing bodies or mission drift in how the code is being applied in practice.

The issuing bodies include a county health department (Seminole County, Florida) and a state health and human services agency (Texas Health and Human Services Commission), suggesting that health authorities and state pharmacy programs are the primary buyers. Geographically, recent activity concentrates in Florida and Texas. The Seminole County solicitation (IFB 60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through a competitive bidding process with quarterly deliveries, demonstrating state and local appetite for opioid-crisis response products. The Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) explores vendor capabilities for a direct-to-manufacturer prescription program with negotiated net pricing outside traditional pharmacy benefit manager and group purchasing organization channels. Vendors responding to opportunities in this code space should expect E-Verify compliance, drug-free workplace certification, and federal compliance requirements where FEMA funding is involved; however, the fundamental misalignment between the code name and recent solicitation scope makes this code unreliable for targeting pharmaceutical procurement activity.